BioEphX is a Greenville NC-based startup developing patented lead therapeutic compound "EFNA1". EFNA1 preserves heart tissue following myocardial infarction (heart attack) which otherwise results in morbidity and mortality as a result of heart failure. Direct medical costs associated with coronary disease is $126 billion. Coronary artery bypass surgery (CABG) is an open-heart procedure that involves using a vessel from another location to divert blood around the blockage. Over 300,000 surgeries are performed annually at a cost of $6.7 billion. 13% of these require readmission within 30 days, leading to additional infarct. Our initial target market is treating these patients with EFNA1, with direct and measurable impact to reduce or eliminate remission post CABG. Our long-term goal is for EFNA1 to become a standard of care for all patients with known or at-risk for coronary disease. Our next step is preclinical trials to prepare an U.S. FDA application for human trials. Our team plus consultants have experience and success with this overall process.